FDA Approves InVivo's Human Study to Test Biopolymer for Spinal Cord Injuries

Spinal Tech

InVivo Therapeutics Holdings had its investigational device exemption human trial approved by the FDA for a treatment of spinal cord injuries and neurotrauma conditions. The 15-month study will test a biopolymer scaffold product, which was developed to treat patients with acute traumatic spinal cord injuries. Currently, no FDA-approved treatments exist or are in clinical trials for direct spinal cord intervention, according to the release.

More Articles on Devices:
Stryker Names William Jellison CFO
Biomet Gains Exclusive Distribution Rights to OPM OsteoFab Implants
13 Spine Devices Receive FDA 510(k) Clearance in March

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers